16^th International Conference on Chronic Obstructive Pulmonary Disease November 28-29, 2024 Paris, France

Track 1: Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide. COPD exacerbation is usually treated with antibiotics, systemic corticosteroids, and inhaled bronchodilators. COPD exacerbation was treated repeatedly with standard therapy. Dynamic expiratory computed tomography of the chest was done, which revealed concomitant tracheomalacia. COPD and tracheomalacia may coexist during recurrent exacerbations of COPD, and delayed diagnosis can be associated with severe comorbidities. Ordering the appropriate imaging technique may aid in the correct diagnosis and facilitate appropriate management. COPD Conferences will survey the evolution of pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences | COPD 2024 Conferences | Lung 2024 Conferences

European COPD Societies: Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies: American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society

Track 2: COPD Pathogenesis

Inflammation is present in the lungs, especially the small airway routes, of all people who smoke. COPD Pathogenesis is typical defensive reaction to the inhaled toxins is enhanced in COPD, leading to tissue destruction, debilitation of the defence mechanisms and interruption of the repair mechanisms. In general, the inflammatory and structural changes in the airway routes increased with disease seriousness and hold on even after smoking cessation. Other than inflammation, two different procedures are associated with the pathogenesis of COPD an irregularity amongst proteases and antiproteases and an imbalance amongst oxidants and antioxidants agents in the lungs. Pulmonary Conferences expresses various developing treatments for COPD.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies: Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society

Asian COPD Societies: Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

Track 3: Asthma and COPD

Bronchial Asthma and Chronic Obstructive Pulmonary Disease are obstructive pneumonic sicknesses that influenced a large number of people everywhere throughout the world. Chronic Obstructive Pulmonary Disease (COPD) is a group of pulmonary diseases that block air stream in the lungs. Asthma is a chronic disease noticeable by spasms of bronchi, due to inflamed and narrowed airways in the lungs. Asthma causes difficulty in breathing that often results from an allergic reaction. There is large evidence that treatment with anti-inflammatory drugs reduces morbidity and mortality in asthma. Inhaled corticosteroids appear to have a place in the management of severe chronic obstructive pulmonary disease, perhaps by decreasing the frequency of exacerbations. Lung Conferences envelop the fields of asthma and COPD which have important similarities and differences. Asthma and COPD are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both result from gene environment communications and both are typically characterized by mucus and bronchoconstriction.

COPD Conferences | Pulmonary Conferences | Lung Conferences | Conference 2024

European COPD Societies: The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation; Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations

USA COPD Societies: Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society

Track 4: Epidemiology of COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in responsible for human and economic burden around the world. Cigarette smoking is the fundamental hazard factor for COPD in the developed world, although other essential respiratory disorder incorporate word related exposures, air contamination, airway route hyper responsiveness, asthma, and hereditary predisposition. In the vast majority of the world, Epidemiology of COPD prevalence and mortality keep on rising in light of increases in smoking addiction, especially by women and adolescents. COPD is likewise an imperative reason for disability, and is connected to comorbid diseases, for example, depression and cardiovascular disease, which adds to the large economic burden related with this issue. Better public health and medical intercessions that target both the risk factors for COPD and look toward prior mediation may decrease growing public health impact of COPD. COPD Conferences will focus on the understanding of all the pulmonary treatments.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation

USA COPD Societies: Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases

Asian COPD Societies: Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

Track 5: COPD Therapeutics

The objective of COPD therapeutics is to enhance a patient's functional status and quality by protecting optimal lung function, enhancing indications, and keeping the recurrence of COPD exacerbations. At present, no medicines aside from lung transplantation have been appeared to significantly enhance lung function or decrease mortality; however, oxygen therapy and smoking cessation may decrease mortality. Once the diagnosis of COPD is established, it is essential to educate the patient about the sickness and to empower their active interest in treatment. Bronchodilators are the foundation of any COPD treatment regimen. They work by enlarging aviation routes, accordingly diminishing airsac protection. Pulmonary Conferences provides a multidisciplinary to pulmonology researchers.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies: Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care

Asian COPD Societies: Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society; Thoracic Society of Australia and New Zealand

Track 6: COPD Exacerbations

Constant Obstructive Pulmonary Disease (COPD) experiences long-term and dynamic damage to their lungs. This impacts air flow to the lungs. Doctors in some cases call this condition chronic bronchitis or chronic emphysema. Those with COPD can experience periods when their signs are much worse than normal. This is known as an acute exacerbation. Shortness of breath and chest tightness is present in many cases. A patient encountering a COPD exacerbation may need to search for medicinal help at a hospital. COPD exacerbations can be harmful because they can make damage to the lungs. COPD, keeping a compounding from happening can enable you to live a healthier life and diminish risk of death. Self-management and prevention for COPD will be beneficial for future exacerbation. Lung Conferences will explore the application of pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Respiratory Society; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Association for Bronchology and Interventional Pulmonology; Cystic Fibrosis Europe; Italian Society for Infant Respiratory Diseases; Italian Society of Pneumology

USA COPD Societies: American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine

Asian COPD Societies: Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Indian Chest Society

Track 7: Types of COPD

People with different types of COPD experience difficulty in breathing and shortness of breath. The two principle infections that fall under the extent of COPD are: Chronic bronchitis, which involves a long-term cough with mucus, it is a long-term inflammation of the bronchi, which results in increased production of mucus, as well as other changes. These changes may result in breathing problems, frequent infections, cough, disability, anxiety and depression. Emphysema, which involves damage to the lungs over time. Emphysema is a chronic lung condition in which alveoli may be: destroyed, narrowed, collapsed, stretched, and over-inflated. This can cause a reduction in respiratory capacity and breathlessness. Harm to the air sacs is irreversible and brings about permanent "holes" in the lung tissue. COPD Conferences will focus on the different techniques used in pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Romanian Society of Pneumology; European Federation of Allergy and Airways Diseases Patient Associations; European Pulmonary Hypertension Association; European Society of Federasma and Allergies; British Lung Foundation; Association for Respiratory Technology and Physiology

USA COPD Societies: Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Saudi Thoracic Society; Chinese Thoracic Society; Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases

Track 8: COPD: Sign and Symptoms

For Chronic Obstructive Pulmonary Disease there are no sign and symptoms or sometimes it may show mild symptoms. As the disease gets inferior, symptoms usually progress more severe. The first symptom of COPD is usually a long-term or chronic cough. If you have COPD, you also may often have colds or other respiratory infections such as the flu, or influenza. Pulmonary Conferences discuss about the COPD symptoms, often don't appear until significant lung damage or lung cancer has occurred, and they usually worsen over time, particularly if smoking exposure continues. Symptoms include increasing breathlessness – this may just occur when exercising at first and you may sometimes wake up at night feeling breathless, a persistent chesty cough with phlegm that never seems to go away, frequent chest infections, persistent wheezing.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Lung Foundation; The Primary Care Respiratory Society UK; European COPD Coalition; Association for Respiratory Technology and Physiology; Italian Society for Infant Respiratory Diseases; Cystic Fibrosis Europe

USA COPD Societies: American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society

Asian COPD Societies: Japanese Respiratory Society; Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Chinese Thoracic Society; Indian Chest Society

Track 9: Genetic risk factor of COPD

Even if an individual has never smoked or been unprotected to pollutants for an extended period of time, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1  in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that each individual determined to have COPD be tested for Alpha-1. Pulmonary Conferences also discusses about different types of genes which may be a cause of pulmonary diseases.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations; European Lung Foundation; the Primary Care Respiratory Society UK; Italian Society of Pneumology

USA COPD Societies: Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 10: Lung cancer

Patients with chronic obstructive pulmonary disease are at increased risk for both the development of primary lung cancer, as well as poor outcome after lung cancer diagnosis and treatment. Because of existing impairments in lung function, patients with COPD often do not meet traditional criteria for tolerance of definitive surgical lung cancer therapy. Emerging information with respect to the pathophysiology of COPD in lung resection demonstrates that postoperative decrements in lung capacity may be less than anticipated by traditional prediction tools. In patients with COPD, more inclusive consideration for surgical resection with curative intent might be appropriate as constrained surgical resections or nonsurgical therapeutic options provide inferior survival. Besides, optimizing perioperative COPD therapeutic care as indicated by clinical practice rules including smoking cessation can possibly minimize morbidity and enhance functional status in this often severely impaired patient population. Lung Conferences concentrates on the risk factor for development of lung cancer.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; British Lung Foundation               

USA COPD Societies: American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology

Asian COPD Societies: Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Thoracic Society of Australia and New Zealand

Track 11: COPD and Cardiovascular Diseases

Chronic obstructive pulmonary disease is related with increased risk of cardiovascular disease, for example, heart failure or a heart attack. The lungs and the heart work firmly together to supply the oxygen; oxygen in the air that comes into the lungs is moved into the circulation system, which the heart at that point pushes out to rest of the body. But diseases in both the heart and the lungs often go together. If person have COPD then there is a higher risk of having cardiovascular diseases. Comorbidities and chronic obstructive pulmonary disease (COPD) are pervasive, with cardiovascular disease being the most well-known and significant. Risk factors for COPD and Cardiovascular Diseases, such as smoking, low socioeconomic class, and a sedentary lifestyle contribute to the natural history of each of these conditions. COPD Conferences will focus on the scope of COPD related to cardiovascular diseases.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies: Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology

Asian COPD Societies: Chinese Thoracic Society; Indian Chest Society; Chinese Association of Chest Physicians; Japanese Respiratory Society; Philippine College of Chest Physicians

Track 12: Pulmonary Hypertension

Pulmonary hypertension is a type of high blood pressure that impacts the arteries in lungs and the right side of heart. In one type of pulmonary hypertension, modest arteries in lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through lungs, and raises pressure inside the arteries of lungs. As the pressure builds, heart's lower right chamber (right ventricle) must work harder to direct blood through lungs, in the end causing heart muscle to debilitates and fail. Few categories of pulmonary hypertension are serious conditions that become progressively worse and sometimes become fatal. Pulmonary hypertension can lead to a number of COPD complications such as blood clots in the lungs, sickle cell disease and sleep apnea. Although a few kinds of pulmonary hypertension are not curable, treatment can help decrease symptoms and enhance quality of life. Pulmonary Conferences concentrates on the impact of pulmonary hypertension.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Cystic Fibrosis Europe; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Romanian Society of Pneumology; European Respiratory Society

USA COPD Societies: American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Chinese Association of Chest Physicians; Japanese Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Respiratory Society

Track 13: Pathophysiology of COPD

Chronic obstructive pulmonary disease (COPD) is a life-threatening condition. It affects lungs and ability to breathe. The pathophysiology of COPD is the physical changes associated with it, start with damage to airways and the air sacs in lungs. It progresses from a cough with mucus to difficulty breathing. To understand pathophysiology of COPD, it is essential to understand the structure of the lungs. When you inhale, air moves down in trachea through two tubes called bronchi. The bronchi branch out into smaller tubes called bronchioles. At the ends of the bronchioles are little air sacs called alveoli. And at the end of alveoli are capillaries, which are tiny blood vessels. Lung Conferences envision the pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European COPD Coalition; The Primary Care Respiratory Society UK; Italian Society of Pneumology; Association for Respiratory Technology and Physiology; Italian Society for Infant Respiratory Diseases; British Lung Foundation

USA COPD Societies: Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society

Asian COPD Societies: Saudi Thoracic Society; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Indian Chest Society

Track 14: Co-Morbidities of COPD

Additional pulmonary comorbidities impact the anticipation of patients with COPD. Tobacco smoking is a typical hazard factor for much comorbidity, including coronary illness, heart failure and lung cancer. Comorbidities, for example, pulmonary artery disease and malnutrition are specifically caused by COPD, while others, such as fundamental venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic disorder, diabetes, sleep disturbance and anaemia, have no clear physiopathological association with COPD. Co-Morbidities of COPD shared conviction between the majorities of these extra pulmonary signs is chronic systemic inflammation. These diseases potentiate the morbidity of COPD, prompting expanded hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and should be evaluated and treated adequately. COPD Conferences enlighten the recent advances in COPD and pulmonology research.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; The Primary Care Respiratory Society UK; Italian Society of Pneumology; Romanian Society of Pneumology; European Lung Foundation

USA COPD Societies: Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians

Asian COPD Societies: Chinese Thoracic Society; Thoracic Society of Australia and New Zealand; Chinese Association of Chest Physicians; Indian Chest Society; Philippine College of Chest Physicians

Track 15: COPD Complications

Individuals with COPD can be in risk for serious complications that can not only put their health in jeopardy, but can also be fatal. Cor Pulmonale of COPD bring down extremity edema (swelling) in a patient with COPD Complications is typically an indication of cor pulmonale (pulmonary hypertension and right-sided heart failure). Acute COPD Exacerbations are portrayed by an unexpected increment of manifestations. Cough and sputum production increases. At the point when respiratory failure happens in a patient who slowly, there is a moderate decrease in lung capacity and rising levels of carbon dioxide in the blood. The expanding carbon dioxide makes an opiate impact in the patient, who gradually loses awareness and quits relaxing. Different difficulties of COPD incorporate pneumonia, polycythemia, and pneumothorax. Pneumonia caused by bacterial disease can prompt respiratory failure in these patients. Streptococcus pneumoniae is the most well-known reason for bacterial pneumonia in patients with COPD. Pneumothorax happens when a hole develops in the lung, enabling air to escape into the space between the lung and the chest wall and collapsing the lung. Polycythemia in COPD is the body's endeavour to adjust to decreased amount of blood oxygen by expanding the generation of oxygen-conveying red blood cells. While this might be useful temporarily, overproduction eventually clogs small blood vessels. COPD Conferences provides global forum for discussion about new innovation of pulmonology research.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases

USA COPD Societies: Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Saudi Thoracic Society; Chinese Thoracic Society; Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases

Track 16: Pulmonary diseases-treatment and therapies

There's currently no cure for chronic obstructive pulmonary disease (COPD), yet pulmonary diseases treatment and therapies can help moderate the movement of the condition and control the side effects. Medicines include: quit smoking, inhalers and pharmaceuticals – to help make breathing easier, pulmonary rehabilitation – a specific program of exercise and education surgery or a lung transplant – although this is only an option for a very small number of people. Much of the treatment for COPD includes self-management and prevention of COPD. Oxygen therapy can improve quality of life and is the only COPD therapy proven to extend life. Surgery is an option for some people with some forms of severe emphysema who aren't helped sufficiently by medications alone. Surgical options include: Lung volume reduction surgery, Lung transplant and Bullectomy. COPD Conferences will disclose the application of different treatments and therapies.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation

USA COPD Societies: Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care

Asian COPD Societies: Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society; Thoracic Society of Australia and New Zealand

Track 17: Pediatric Pulmonary, Critical care and Sleep

Much of the focus of pulmonary rehabilitation, research and pneumonic medication goes toward the youngest individuals from society-the newborns. For instance, the reason for pulmonary stenosis is because of improper pulmonary valve improvement in the initial two months of fetal development. It's congenital but treatable. With a sound pulmonary stenosis diagnosis the heart valve can be replaced or repaired and children can grow to lead normal healthy lives. Sleep apnea affects premature babies. A situation called apnea of prematurity exists when the child doesn’t breath for 20 seconds or more. It is a pulmonary disease that can be treated with ventilation machines and medications. COPD Conferences explains about pediatric pulmonary, critical care and sleep which includes Pediatric emergencies, Pneumonia, Respiratory failure, Pediatric in-patient and critical care, Sepsis and Head Trauma & Concussion.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation; Italian Society for Infant Respiratory Diseases

USA COPD Societies: American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine

Asian COPD Societies: Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Indian Chest Society

Track 18: Depression and anxiety in COPD

Depression and anxiety in COPD are regular in patients with chronic obstructive pulmonary disease (COPD), assessments of their pervasiveness differ significantly. These likely reflect the assortment of scales and strategies used to measure such symptoms. Patients with COPD with three or more comorbidities are more likely to be frequently hospitalized and may die prematurely compared to COPD patients without comorbidities.  An uplifted experience of dyspnoea is probably contributing component to anxiety. Feelings of depression may be precipitated by the loss and grief associated with the disability of COPD. Smoking has been associated with nicotine addiction, and the factors that contribute to smoking may also predispose to anxiety and depressive disorders. The cause of depression and anxiety symptoms are multifactorial and include behavioural, social and biological factors. Lung Conferences exhibits randomized controlled trials show that activity exercise training and precisely chose pharmacological treatment are regularly effective in ameliorating anxiety and depression.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies: Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies: Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 19: Drug Discovery of COPD

Chronic obstructive pulmonary disease is an increasing worldwide medical issue and cause of death. COPD predominantly influencing small airway routes and lung parenchyma that prompts dynamic aviation route deterrent. COPD is a standout amongst the most widely recognized infections on the globe, and there is a global increase in prevalence, however there are no drugs available at present that halt the relentless progression of this disease. In any case, a superior comprehension of the cell and molecular mechanisms that are associated with the underlying inflammatory and destructive processes has uncovered a few new focuses for which drugs are presently being developed, and the prospects for finding new medications are good.

European COPD Societies: European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies: Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies:Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 20: Self-Management and Prevention of COPD

Self-Management and Prevention of COPD interventions help patients with chronic obstructive pulmonary disease (COPD) acquire and practise the skills they need to carry out disease-specific medical regimens, guide changes in health behaviour and provide emotional support to enable patients to control their disease. Patients with COPD confirmed by spirometry and symptoms and airflow obstruction should be monitored regularly to guide modification of treatment and to identify complications early Pulmonary Conferences will be focused on the self-management support programmes should be collaborative between healthcare professionals and patients, to help them acquire skills to understand and manage their medications and exacerbations of COPD, adopt healthier behaviours and manage the social-emotional consequences of the disease.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies: Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology

USA COPD Societies: Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies: Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

The Report Covers Chronic Obstructive Pulmonary Disease Treatment Market Trends and it is Segmented by Drug Class (Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs), Indication (Asthma and Chronic Obstructive Pulmonary Disease), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are Provided in terms of value in USD million for all the above segments.

Asthma and COPD Drugs Market Analysis

Asthma and COPD drugs market is expected to witness a CAGR of 4.6% during the forecast period.

COVID-19 had a significant impact on the growth of the market during the pandemic period. Chronic obstructive pulmonary disease (COPD) patients had an increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptors in small airways. An NCNI article published in March 2022, mentioned that COPD is associated with worse clinical outcomes from COVID-19. Also, according to a research study published in the Nature Journal in February 2021, in South Korea, among the COVID-19 infected patients who are 40 years and older, 3.1% had COPD; of these 7.1% received ICU care, and 5.7% received mechanical ventilation. Thus, the COVID-19 pandemic had a significant impact on the asthma and COPD drugs market.

Some of the factors that are driving the market growth include an increase in the incidence and prevalence of asthma and COPD, advanced therapeutic drugs, and a growing geriatric population.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. According to the NCBI article published in March 2022, the estimated pooled prevalence of COPD was 11.1% in South Asian countries in 2021. The report also mentioned that the prevalence of COPD was highest in North India (19.4%) and Bangladesh (13.5%). Moreover, the increasing geriatric population globally is boosting the market growth. According to the WHO data published in October 2022, the population aged 60 years and over will increase to 1.4 billion in 2030 and is expected to reach 2.1 billion by 2050. The UN report in 2022 mentioned that the share of the population aged 65 years or over is projected to rise from 10% in 2022 to 16% in 2050. As, the geriatric population is most prone to developing asthma conditions, the increase in the geriatric population is expected to contribute to the growth of the market.

In addition, technological advancements are anticipated to provide the market with lucrative opportunities. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby boosting the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial was expected to be completed in July 2024.

The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, in June 2021, Valeo Pharma Inc. commercially launched the Enerzair Breezhaler and Atectura Breezhaler for the treatment of asthma patients in Canada. These products have demonstrated that they improve the level of control of asthma symptoms and better prevent related complications.

Thus, the factors such as an increase in the incidence and prevalence of asthma and COPD, advanced therapeutic drugs, and increasing product developments are expected to contribute to the growth of the market. However, factors such as stringent government regulations for product approvals and side effects associated with drugs are expected to impede market growth over the forecast period.

Asthma and COPD Drugs Market Trends

This section covers the major market trends shaping the Asthma & COPD Drugs Market according to our research experts:

The Asthma Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Asthma is considered one of the world's most common diseases affecting the population and a life-threatening condition affecting patients' regular breathing. It is a persistent condition that stretches and narrows the air passages of the lungs, causing constant assaults of breathlessness, bronchospasm, and reversible obstruction of airflow. Moreover, there is a large rise in the consumption of cigarettes, which contributes to asthma symptoms. In addition, the rise in industrialization has also contributed to an increase in the number of cases of asthma, which is expected to drive the growth of the studied segment.

The substantial increase in the prevalence and incidence of asthma has increased the patient population, increasing the demand for these drugs. According to the Australian Bureau of Statistics data 2021, over 2.7 million Australians had asthma in 2021. The data also mentioned that females were more likely to have asthma (12% compared to 9.4%). Enormous investments in the study of asthma drugs accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market.

For instance, in March 2021, GlaxoSmithKline PC, in collaboration with Iqvia Pty Ltd, initiated a Phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial was expected to be completed in October 2023. Similarly, in February 2021, AstraZeneca PLC, in collaboration with Amgen Inc., initiated a Phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged 5 to 11 years with asthma. The trial was expected to be completed in September 2021. Thus, the aforementioned factors
such as an increase in the prevalence and incidence of asthma and rising product developments are expected to drive segment growth over the forecast period.